Niraj Shenoy, MD, PhD, MS
@nirajshenoy
Physician-Scientist. Cancer Biologist. GU Oncologist. Associate Professor @NUFeinbergMed @NorthwesternMed. PI, Shenoy Lab @LurieCancer. Dir, Kidney Cancer Res
ID: 1099052676879474688
https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=53456 22-02-2019 21:05:52
62 Tweet
169 Followers
101 Following
Underexpression of the metabolic enzyme SDH is a common and adverse #epigenetic modulating feature in ccRCC according to findings from Lurie Cancer Center’s Niraj Shenoy, MD, PhD, MS, published in PNASNews news.feinberg.northwestern.edu/2021/10/study-… via Northwestern Feinberg School of Medicine #kidneycancer
Feinberg has been selected as the home of the Journal of Clinical Investigation (Journal of Clinical Investigation) for its next five-year term, and Elizabeth McNally, MD, PhD, will serve as the journal’s next editor-in-chief. spr.ly/6015JvVXN
.Daniel Brat, MD, PhD, MD, PhD, chair of Northwestern Pathology and a member of Lurie Cancer Center, has been heavily involved in the process of moving molecular genetic #biomarkers for #glioma from the lab to clinical practice. Read more: news.feinberg.northwestern.edu/2022/03/pathol… via Northwestern Feinberg School of Medicine #neuropath
Thank you so much, Lynne Elmore. It was great having you here. Could not be more grateful to ACS Research for all the support!
Does the addition of ipilimumab to standard-dose nivolumab safely improve clinical outcomes in patients with advanced cancers other than melanoma? Read the findings from Lurie Cancer Center investigators Niraj Shenoy, MD, PhD, MS and Anthony Serritella in JAMA Oncology jamanetwork.com/journals/jamao…
A meta-analysis from Niraj Shenoy, MD, PhD, MS in JAMA Oncology revealed that in advanced cancers other than melanoma, the addition of ipilimumab to standard-dose nivolumab was not associated with clinically meaningful improvement. news.feinberg.northwestern.edu/2023/09/21/com… Anthony Serritella